Portal de investigación
Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Reck, M
- Ciuleanu, TE
- Dols, MC
- Schenker, M
- Zurawski, B
- Menezes, J
- Richardet, E
- Bennouna, J
- Felip, E
- Alexandru, A
- Sakai, H
- Scherpereel, A
- Lu, S
- John, T
- Carbone, DP
- Meadows-Shropshire, S
- Yan, J
- Paz-Ares, LG
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Reck,M,Ciuleanu,TE,Dols,MC,Schenker,M,Zurawski,B,Menezes,J,Richardet,E et al. Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND:KARGER. 2020 p.p. 140-140.